Goutham Sunny: Lutetium-177–PSMA-617 or Cabazitaxel in Metastatic Prostate Cancer
Goutham Sunny, Former Resident Doctor at The Gujarat Cancer and Research Institute, posted on X:
“In the TheraP trial for mCRPC, ctDNA unlocks new biomarker insights for Lu–PSMA-617!
180 PSMA PET-selected pts, 290 cfDNA samples analyzed.
- Low ctDNA = better PSA50 response (100% vs 58%)
- PFS boost: 14.7 vs 6.0 mo (HR 0.12) — independent of PET!
- PTEN loss = worse on cabazitaxel
- ATM defects = potential benefit with [¹⁷⁷Lu]Lu–PSMA-617.
- Resistance? No single gene driving it
- tDNA dynamics and genomic profiling = next-gen tools for precision PSMA therapy!”
Title: Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
Authors: Edmond M. Kwan, Sarah W. S. Ng, Sofie H. Tolmeijer, Louise Emmett, Shahneen Sandhu, James P. Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Vinod Subhash, Sze-Ting Lee, Andrew M. Scott, Andrew J. Martin, Martin R. Stockler, Gráinne Donnellan, Matti Annala, Cameron Herberts, Ian D. Davis, Michael S. Hofman, Arun A. Azad, Alexander W. Wyatt
Read The Full Article at Nature Medicine.
More posts featuring Goutham Sunny.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023